These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7693039)

  • 1. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
    te Boekhorst PA; de Leeuw K; Schoester M; Wittebol S; Nooter K; Hagemeijer A; Löwenberg B; Sonneveld P
    Blood; 1993 Nov; 82(10):3157-62. PubMed ID: 7693039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
    Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
    Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
    Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia.
    Hart SM; Ganeshaguru K; Lyttelton MP; Prentice HG; Hoffbrand AV; Mehta AB
    Leuk Lymphoma; 1993 Oct; 11(3-4):239-48. PubMed ID: 7903178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells.
    Lautier D; Bailly JD; Demur C; Herbert JM; Bousquet C; Laurent G
    Int J Cancer; 1997 Apr; 71(2):292-9. PubMed ID: 9139856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
    Leith CP; Chen IM; Kopecky KJ; Appelbaum FR; Head DR; Godwin JE; Weick JK; Willman CL
    Blood; 1995 Sep; 86(6):2329-42. PubMed ID: 7545025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
    Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
    Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
    Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
    Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
    Marcelletti JF; Sikic BI; Cripe LD; Paietta E
    Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of P glycoprotein activity on normal and leukemic CD34+ cells.
    Drenou B; Fardel O; Amiot L; Fauchet R
    Leuk Res; 1993 Dec; 17(12):1031-5. PubMed ID: 7504150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia.
    Pallis M; Turzanski J; Harrison G; Wheatley K; Langabeer S; Burnett AK; Russell NH
    Br J Haematol; 1999 Feb; 104(2):307-12. PubMed ID: 10050713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
    Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
    Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
    Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
    Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.
    Campos L; Guyotat D; Archimbaud E; Calmard-Oriol P; Tsuruo T; Troncy J; Treille D; Fiere D
    Blood; 1992 Jan; 79(2):473-6. PubMed ID: 1370388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.